Cargando…
COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd on behalf of The British Infection Association.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212499/ https://www.ncbi.nlm.nih.gov/pubmed/35718206 http://dx.doi.org/10.1016/j.jinf.2022.06.011 |
| _version_ | 1784730610284101632 |
|---|---|
| author | Coulson, J.M. Adams, A. Gray, L.A. Evans, A. |
| author_facet | Coulson, J.M. Adams, A. Gray, L.A. Evans, A. |
| author_sort | Coulson, J.M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212499 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Ltd on behalf of The British Infection Association. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92124992022-06-22 COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy Coulson, J.M. Adams, A. Gray, L.A. Evans, A. J Infect Letter to the Editor Published by Elsevier Ltd on behalf of The British Infection Association. 2022-10 2022-06-17 /pmc/articles/PMC9212499/ /pubmed/35718206 http://dx.doi.org/10.1016/j.jinf.2022.06.011 Text en Crown Copyright © 2022 Published by Elsevier Ltd on behalf of The British Infection Association. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Coulson, J.M. Adams, A. Gray, L.A. Evans, A. COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy |
| title | COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy |
| title_full | COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy |
| title_fullStr | COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy |
| title_full_unstemmed | COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy |
| title_short | COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy |
| title_sort | covid-19 “rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212499/ https://www.ncbi.nlm.nih.gov/pubmed/35718206 http://dx.doi.org/10.1016/j.jinf.2022.06.011 |
| work_keys_str_mv | AT coulsonjm covid19reboundassociatedwithnirmatrelvirritonavirprehospitaltherapy AT adamsa covid19reboundassociatedwithnirmatrelvirritonavirprehospitaltherapy AT grayla covid19reboundassociatedwithnirmatrelvirritonavirprehospitaltherapy AT evansa covid19reboundassociatedwithnirmatrelvirritonavirprehospitaltherapy |